Richter transformation of chronic lymphocytic leukaemia in the era of treatment with B-cell signalling pathway inhibitors

Czech version

Authors: M. Špaček
Authors‘ workplace: I. interní klinika – klinika hematologie, 1. lékařská fakulta, Univerzita Karlova a Všeobecná fakultní nemocnice v Praze
Published in: Transfuze Hematol. dnes,26, 2020, No. 1, p. 9-17.
Category: Review/Educational Papers

Overview

Richter transformation (RT) is a severe complication of chronic lymphocytic leukaemia (CLL) affecting up to approximately 10% of patients with CLL. Most patients develop transformation to diffuse large B-cell lymphoma (DLBCL), which carries a dismal prognosis with a median survival of less than one year. Clinical and laboratory features suggestive of RT include elevated lactate dehydrogenase, bulky or rapidly enlarging lymph nodes and B-symptoms. PET/CT scan can identify optimal site for excisional biopsy, which is a prerequisite for final RT diagnosis. Chemoimmunotherapy remains the standard-of-care for RT, followed by stem cell transplantation in eligible patients. However, patients with RT are frequently elderly with comorbidities and poor performance status limiting intense chemotherapy or transplantation. This review focuses on diagnosis, clinicopathological features, development and treatment of RT in the era of novel targeted agents.

Keywords:

chronic lymphocytic leukaemia – Richter transformation – ibrutinib – idelalisib – venetoclax

Sources

1. Parikh SA, Kay NE, Shanafelt TD. How we treat Richter syndrome. Blood. 2014;123(11):1647–1657.

2. Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol. 2008;142(2):202–215.

3. Allan JN, Furman RR. Current trends in the management of Richter’s syndrome. Int J Hematol Oncol. 2018;7(4):IJH09.

4. Wang Y, Tschautscher MA, Rabe KG, et al. Clinical characteristics and outcomes of Richter transformation: Experience of 204 patients from a single center. Haematologica; [on-line] 2019. DOI 10.3324/haematol.2019.224121.

5. Bruzzi JF, Macapinlac H, Tsimberidou AM, et al. Detection of Richter’s transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med. 2006;47(8):1267–1273.

6. Mauro FR, Chauvie S, Paoloni F, et al. Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. Leukemia. 2015;29(6):1360–1365.

7. Falchi L, Keating MJ, Marom EM, et al. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014;123(18):2783–2790.

8. Mato AR, Wierda WG, Davids MS, et al. Utility of PET-CT in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. Haematologica. 2019;104(11):2258–2264.

9. Rhodes JM, Mato AR. PET/Computed tomography in chronic lymphocytic leukemia and Richter transformation. PET Clin. 2019;14(3):405–410.

10. Ronchi A, Marra L, Frigeri F, et al. Richter syndrome with plasmablastic lymphoma at primary diagnosis: a case report with a review of the literature. Appl Immunohistochem Mol Morphol. 2017;25(6):e40–e45.

11. Mao Z, Quintanilla-Martinez L, Raffeld M, et al. IgVH mutational status and clonality analysis of Richter’s transformation. Am J Surg Pathol. 2007;31(10):1605–1614.

12. Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117(12):3391–3401.

13. Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood 2018;131(25):2761–2772.

14. Soilleux EJ, Wotherspoon A, Eyre TA, et al. Diagnostic dilemmas of high-grade transformation (Richter’s syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review. Histopathology. 2016;69(6):1066–1076.

15. Khan M, Siddiqi R, Thompson PA. Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies. Ann Hematol. 2018;97(1):1–15.

16. Gine E, Martinez A, Villamor N, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica. 2010;95(9):1526–1533.

17. Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2017.

18. Parikh SA, Rabe KG, Call TG, et al. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol. 2013;162(6):774–782.

19. Solh M, Rai KR, Peterson BL, et al. The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). Leuk Lymphoma. 2013;54(2):252–254.

20. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370(9583):230–239.

21. Maurer C, Langerbeins P, Bahlo J, et al. Effect of first-line treatment on second primary malignancies and Richter’s transformation in patients with CLL. Leukemia. 2016;30(10):2019–2025.

22. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322.

23. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 2016;17(6):768–778.

24. Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18(2):230–240.

25. Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(1):65–75.

26. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120.

27. Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223.

28. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.

29. Sharman JP, Coutre SE, Furman RR, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019;37(16):1391–1402.

30. Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–332.

31. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437.

32. O’Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood. 2015;126(25):2686–2694.

33. Langerbeins P, Busch R, Anheier N, et al. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol. 2014;89(12):E239–E243.

34. Eyre TA, Clifford R, Bloor A, et al. NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome. Br J Haematol. 2016;175(1):43–54.

35. Rogers KA, Huang Y, Ruppert AS, et al. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol. 2018;180(2):259–266.

36. Cwynarski K, van Biezen A, de Wreede L, et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter’s syndrome): a retrospective analysis from the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012;30(18):2211–2217.

37. Doubek M, Špaček M, Pospíšilová Š, et al. Doporučení pro diagnostiku a léčbu chronické lymfocytární leukemie (CLL) – 2018. Transfuze Hematol Dnes. 2018;24(3):208–220.

38. Tsang M, Shanafelt TD, Call TG, et al. The efficacy of ibrutinib in the treatment of Richter syndrome. Blood. 2015;125(10):1676–1678.

39. Visentin A, Imbergamo S, Scomazzon E, et al. BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome. Br J Haematol. 2019;185(1):193–197.

40. Hillmen P, Schuh A, Eyre TA, et al. Acalabrutinib monotherapy in patients with Richter transformation from the phase 1/2 ACE-CL-001 clinical study. Blood. 2016;128(22):60.

41. Davids MS, Roberts AW, Seymour JF, et al. Phase i first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol. 2017;35:826–833.

42. Ding W, LaPlant BR, Call TG, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017;129(26):3419–3427.

43. Rogers KA, Huang Y, Dotson E, et al. Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre. Br J Haematol. 2019;185(2):363–366.

44. Kuruvilla J, Byrd JC, Flynn JM, et al. The oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) demonstrates broad and durable clinical activity in relapsed / refractory non Hodgkin’s lymphoma (NHL). Blood. 2014;124(21):396.

45. Xia L, Wang Y, Li T, et al. The clinical study on treatment of CD19-directed chimeric antigen receptor-modified T cells in a case of refractory Richter syndrome. Cancer Med. 2019;8(6):2930–2941.

46. Palomba ML, Batlevi C, Riviere I, et al. A phase I first-in-human clinical trial of CD19-targeted 19-28Z/4-1BBL “armored” CAR T cells in patients with relapsed or refractory NHL and CLL including Richter transformation. HemaSphere. 2019;3:755.

47. Jain N, Ferrajoli A, Basu S, et al. A phase II trial of nivolumab combined with ibruti ib for patients with Richter transformation. Blood. 2018;132(Suppl 1):296.

48. Mato AR, Svoboda J, Luning Prak ET, et al. Phase I/II study of umbralisib (TGR-1202) in combination with ublituximab (TG-1101) and pembrolizumab in patients with relapsed/refractory CLL and Richter’s transformation. Blood. 2018;132(Suppl 1):297.

49. Davids MS, Thompson PA, Rogers KA, et al. Initial results of a multicenter phase 2 study of venetoclax in combination with dose-adjusted R-EPOCH for patients with Richter’s syndrome (CRC-043). Hematol Oncol. 2019;37:134–135.

50. Appleby N, Eyre TA, Cabes M, et al. The STELLAR trial protocol: A prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease. BMC Cancer. 2019;19(1):471.